Zydus Life Soars: Ahmedabad Unit Clears USFDA Inspection with Zero Observations

• Zydus Lifesciences' Ahmedabad Injectable Medical Devices facility cleared a USFDA pre-approval inspection (PAI) with zero observations.
• The inspection at Unit-9, Zydus Biotech Park, Changodar, took place from February 16 to 19, 2026.
• A clean inspection is a positive regulatory signal, crucial for future product launches in the US market, especially for injectables.
• Zydus also received USFDA approval for bosentan tablets (for pulmonary arterial hypertension) and launched ANYRA for eye care.
• Zydus shares closed nearly 1% lower on February 19 at ₹901.35, with a 1.5% decline year-to-date.